20% off: Here's why I think the Cochlear (ASX:COH) share price is a buy today

The Cochlear share price is 20% lower than its February high. Here's why I think it might be a good buying opportunity for investors today.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cochlear Limited (ASX: COH) shares have not had a good year in 2020 so far. After topping out at a new (and still standing) all-time high of $251.55 back in February, the Cochlear share price is today asking just $200.50 at the time of writing. That's more than a 20% discount to the February high watermark. Now just because a share has pulled back 20% from its most recent high, this does not mean it's automatically 'on sale' or a 'good deal'. But it does merit some digging in my view, particularly when the company in question is as high calibre as Cochlear.

cheap cochlear share price represented by large green letters spelling out twenty percent

Image source: Getty images

Lend me your ears…

Cochlear is one of the most successful ASX shares in the healthcare space. It famously pioneered the 'Cochlear implant' – a hearing aid device now universally recognisable. The company has continued to remain in the vanguard of hearing aid technology and is still a market leader in the space. It now has a truly global presence, with 20% of its sales now coming from emerging markets. It holds a 60% share of its global product market.

However, like many ASX companies, both Cochlear and its shares have been under pressure this year due to the coronavirus pandemic. In its FY2020 earnings report released last month, Cochlear reported a loss of $238.3 million for the year on revenues of $1.35 billion, mostly due to surgery deferrals as a result of the pandemic. As such, the company will not be paying a final dividend in 2020.

Why is the Cochlear share price a buy today then?

I think Cochlear is worth a good look today, even after its disappointing earnings report. Yes, Cochlear has taken a massive hit this year. But the market that it serves (people with a hearing impairment) hasn't gone anywhere. Cochlear serves a large customer base with inelastic demand for its products. Many of the company's patients are born with a hearing impairment, which means they have a fair chance of being Cochlear customers for life. The company already has a dominant position in advanced economies around the world and as incomes rise in emerging markets, more and more potential customers are finding Cochlear as well.

As such, I think the pullback we've seen in the Cochlear share price this year presents a solid buying opportunity. Quality companies like Cochlear don't go on sale often, and so I think this is a rare chance to open a position or double-down if you already have one.

Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Devastated woman sits near smartphone on home kitchen floor troubled with loneliness.
Healthcare Shares

Which beaten down ASX healthcare stock is a better buy right now: Pro Medicus vs Cochlear shares

Which do experts prefer?

Read more »

Health professional working on his laptop.
Healthcare Shares

Already up 42% this year, Morgans says this ASX healthcare stock can continue to rocket

This broker sees big upside for this healthcare stock.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

This ASX small-cap healthcare stock could rocket more than 50%: Morgans

Share price weakness could present an opportunity.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

Guess which ASX 300 stock was given a big boost from the US FDA

This healthcare stock has made a positive announcement today.

Read more »

A man in a business suit rides a graphic image of an arrow that is rebounding on a graph.
Broker Notes

Down 43% this week, are Cochlear shares now the best bargain buy of the year?

A leading analyst believes the historic selloff in Cochlear shares could present a unique buying opportunity.

Read more »

Young businesswoman sitting in kitchen and working on laptop.
Healthcare Shares

Down 50%, why I'd invest $20,000 into CSL shares

A 50% decline in a blue-chip share can signal trouble, but not always a broken story.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

This ASX biotech stock could deliver 40%-plus returns Morgans says

This small company continues to kick goals.

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward.
Healthcare Shares

How high could Cochlear shares bounce back? Brokers disagree

Despite bad news on the earnings front this week, Cochlear shares could still deliver upside.

Read more »